J-147

The downside for J-147 is unusually benign, which is the main reason it scores at the top of this batch. It is derived from curcumin, showed low toxicity in animals, and passed a Phase 1 trial without a reported safety halt, so there is no demonstrated intrinsic harm to score.

The real concerns are not the molecule itself. They are the missing human dose, which makes self-dosing guesswork, and the gray-market supply, where purity depends on a vendor. The dimensions below keep safety low while flagging those practical risks.

Safety Risk (2.0/5.0): J-147 has no demonstrated intrinsic catastrophic effect. Animal studies reported no mortality or organ toxicity at effective doses, and one late-life study improved rather than worsened kidney markers (Kepchia et al. 2021).

A completed Phase 1 trial (NCT03838185) with no publicly reported halt adds mild reassurance, though its safety data was never released. Safety stays low rather than at the floor because a compound with no published human adverse-event profile still carries genuine unknowns that a proven-safe supplement would not.

Side Effect Profile (1.8/5.0): At the doses studied in animals, J-147 was well tolerated, with no biochemical toxicity flagged in the aging or Alzheimer's studies. There is no human side-effect data to report, so this dimension reflects the mild profile seen in animals rather than a measured human complaint rate.

The realistic human concerns, if J-147 were dosed correctly, would be mild rather than organ-specific, which keeps side effects toward the low end while acknowledging the human profile is unmeasured.

Financial Cost (2.6/5.0): There is no legitimate channel to price, because J-147 is neither an approved drug nor a supplement. The only route is a research-chemical vendor, which lands mid-range on cost but carries the no-legitimate-channel problem.

A buyer pays an ordinary research-chemical price for a product with no manufacturing oversight and no guarantee it contains what the label claims, which is a poor value proposition regardless of the dollar figure.

Time and Effort Burden (1.6/5.0): Oral dosing is simple in principle, a small daily commitment rather than an appointment or procedure. The short brain half-life implies split dosing to sustain any effect, which adds a little burden.

Anyone using gray-market powder also has to weigh and prepare doses without an approved product. On balance this is a low-effort intervention to administer, with the caveat that self-preparation adds an error surface a labeled product would not.

Opportunity Cost (2.3/5.0): For cognition and longevity, J-147 competes with better-evidenced options, from sleep and exercise to compounds with human data like rapamycin and metformin.

Choosing an untested research chemical over any of those means accepting unknown risk for an unproven human benefit, which is a real opportunity cost even though J-147 does not physically interfere with other interventions. The score reflects the presence of concrete, better-established alternatives for the same goals.

Dependency and Withdrawal (1.2/5.0): J-147 has no addictive mechanism, no craving, no tolerance, and no withdrawal syndrome. It is a neurotrophic and metabolic-signaling modulator, so stopping it simply returns signaling toward baseline. The loss of benefit on stopping is a durability matter, scored above, rather than a dependency one, which places dependency at the floor.

Reversibility (1.3/5.0): J-147 appears to clear cleanly. Its short brain half-life means the compound itself washes out quickly, with no evidence of a permanent structural change and no taper described.

The mechanism is a live signal that stops when the compound is gone, so stopping is clean in the sense that matters here. The score sits near the floor, with the honest caveat that clean washout is inferred from animal pharmacokinetics rather than measured in people.